As a multifactorial disease, it is expected that multitarget therapies will be designed for AD, including oxidative stress as a critical component that complements the main therapies against Aβ, tau, neurotransmitters, and neuroinflammation. This evidence concerns the gene MAPT and Alzheimer disease.